Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A British Thoracic Oncology Group Phase III Trial of Gemcitabine Plus Cisplatin at 80mg/m Versus Gemcitabine Plus Carboplatin At 50 mg/m Versus Gemcitabine Plus Carboplatin AUC 6 in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC).

Next Previous
X
Search
Trial Profile

A British Thoracic Oncology Group Phase III Trial of Gemcitabine Plus Cisplatin at 80mg/m Versus Gemcitabine Plus Carboplatin At 50 mg/m Versus Gemcitabine Plus Carboplatin AUC 6 in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC).

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Oct 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemcitabine (Primary) ; Carboplatin; Cisplatin
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms BTOG2

    • Most Recent Events

    • 03 Aug 2017 Primary endpoint (Length of survival, GC50 vs GCb6 and GC80) has not been met as per the results published in the European Journal of Cancer.
    • 03 Aug 2017 Primary endpoint (Length of survival, GCb6 vs GC80) has been met as per the results published in the European Journal of Cancer.
    • 03 Aug 2017 Primary endpoint (Length of survival) has not been met as per the results published in the European Journal of Cancer.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top